136 related articles for article (PubMed ID: 15483014)
1. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
2. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
3. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.
Thomas SK; Cha SC; Smith DL; Kim KH; Parshottam SR; Rao S; Popescu M; Lee VY; Neelapu SS; Kwak LW
BMC Cancer; 2018 Feb; 18(1):187. PubMed ID: 29439670
[TBL] [Abstract][Full Text] [Related]
5. Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.
Tusé D; Ku N; Bendandi M; Becerra C; Collins R; Langford N; Sancho SI; López-Díaz de Cerio A; Pastor F; Kandzia R; Thieme F; Jarczowski F; Krause D; Ma JK; Pandya S; Klimyuk V; Gleba Y; Butler-Ransohoff JE
Biomed Res Int; 2015; 2015():648143. PubMed ID: 26425548
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.
Brody J; Levy R
Immunotherapy; 2009 Sep; 1(5):809-24. PubMed ID: 20636025
[TBL] [Abstract][Full Text] [Related]
7. Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy.
Kundu M; Greer YE; Dine JL; Lipkowitz S
Cells; 2022 Nov; 11(23):. PubMed ID: 36496977
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders.
Nakid-Cordero C; Baron M; Guihot A; Vieillard V
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921413
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccines for aggressive B-cell lymphoma.
Xu-Monette ZY; Young KH
Leuk Lymphoma; 2020 Dec; 61(13):3038-3051. PubMed ID: 32840404
[TBL] [Abstract][Full Text] [Related]
10. Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20
Granot N; Rezvani AR; Pender BS; Storer BE; Sandmaier BM; Storb R; Maloney DG
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1811-1818. PubMed ID: 32693210
[TBL] [Abstract][Full Text] [Related]
11. Uncovering missed indels by leveraging unmapped reads.
Hasan MS; Wu X; Zhang L
Sci Rep; 2019 Jul; 9(1):11093. PubMed ID: 31366961
[TBL] [Abstract][Full Text] [Related]
12. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
[TBL] [Abstract][Full Text] [Related]
13. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
Pierpont TM; Limper CB; Richards KL
Front Oncol; 2018; 8():163. PubMed ID: 29915719
[TBL] [Abstract][Full Text] [Related]
14. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
[TBL] [Abstract][Full Text] [Related]
15. A simple, clinically relevant therapeutic vaccine shows long-term protection in an aggressive, delayed-treatment B lymphoma model.
Pradhan P; Leleux J; Liu J; Roy K
JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202455
[TBL] [Abstract][Full Text] [Related]
16. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
[TBL] [Abstract][Full Text] [Related]
17. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
Sun C; Dotti G; Savoldo B
Blood; 2016 Jun; 127(26):3350-9. PubMed ID: 27207792
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.
Baecklund F; Foo JN; Bracci P; Darabi H; Karlsson R; Hjalgrim H; Rosenquist R; Adami HO; Glimelius B; Melbye M; Conde L; Liu J; Humphreys K; Skibola CF; Smedby KE
BMC Med Genet; 2014 Oct; 15():113. PubMed ID: 25294155
[TBL] [Abstract][Full Text] [Related]
20. Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.
Roehnisch T; Then C; Nagel W; Blumenthal C; Braciak T; Donzeau M; Böhm T; Flaig M; Bourquin C; Oduncu FS
J Transl Med; 2014 May; 12():119. PubMed ID: 24885819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
